Ziopharm raises $50m, advancing PhIII palifosfamide for metastatic soft tissue sarcoma
This article was originally published in Scrip
Executive Summary
Ziopharm Oncology, a US development stage company, has raised $50.2 million through the sale of 9.65 million shares at $5.20 per share in order to continue to advance its pipeline.